Prof. Michael Carrier publishes “The Right to Repair, Competition, and Intellectual Property” in the ABA/IP section’s Landslide magazine. Manufacturers have made it difficult for consumers to repair their products. And they have justified their restrictions in large part by claiming the need to protect their intellectual property (IP). This essay explains how justifications based on … Continue reading Prof. Michael Carrier publishes The Right to Repair, Competition, and Intellectual Property…
Category: Announcements
Prof. Michael Carrier & Alex Moss urge DOJ Antitrust Division to reconsider business review letter
On behalf of 28 former government officials, professors, & public interest advocates, Alex Moss and Prof. Michael Carrier urged the DOJ Antitrust Division to reconsider a business letter supporting the Avanci patent pool that targets the automotive industry. We explain that the letter 1) undermines bipartisan consensus, (2) relies on questionable positions, (3) expresses … Continue reading Prof. Michael Carrier & Alex Moss urge DOJ Antitrust Division to reconsider business review letter…
Prof. Michael Carrier to give lecture in Distinguished Speaker Series at St. Louis University
Prof. Michael Carrier will present his article “Three Challenges for Pharmaceutical Antitrust” as part of the Distinguished Speaker Series at St. Louis University on Thursday, Feb. 2. Available via Zoom! Register here: https://forms.gle/86sd2gkmZH8yw8TLA #HealthLaw
Prof. Michael Carrier to give talks at NY bar association and European University Institute
Prof. Michael Carrier will give talks at (1) the N.Y. State Bar Association on patent settlements and patent thickets and (2) the European University Institute on standard essential patents and an aspect of global litigation known as “anti-suit Injunctions.”
Prof. Michael Carrier to give talk to state antitrust enforcers
Prof. Michael Carrier will give a talk to the antitrust section of the Pharmaceutical Industry Working Group for the National Association of Attorneys General. He will discuss leading issues relating to competition between biologic medicines and more affordable biosimilars.